Monday 21st September 2020

JOINT BASL/BLTG
OVER AND UNDERNUTRITION IN THE CIRRHOTIC PATIENT

13.30-14.10 – Session 1: Over and Undernutrition in the Cirrhotic Patient (1)
Chairs: Professor Guru Aithal & Mr Krish Menon

13.30-13.45 The burden of NASH in the UK and Europe
Dr William Alazawi

13.45-14.00 Bariatric Surgery for NAFLD and its role in the cirrhotic patient being considered for liver transplantation
Professor Jeremy Tomlinson

14.00-14.10 Q&A Session and Panel Discussion

14.10-14.15 BREAK

14.15-14.55 – Session 2: Over and Undernutrition in the Cirrhotic Patient (2)
Chairs: Dr Jo Leithead & Dr Varuna Aluvihare

14.15-14.30 Sarcopenia in liver disease: clinical relevance and potential underlying mechanisms
Professor Janet Lord

14.30-14.45 Nutritional Intervention in the patient with Cirrhosis
Dr Giles Major

14.45-14.55 Q&A Session and Panel Discussion

14.55-15.25 BREAK & VIRTUAL EXHIBITION

15.25-15.55 – Session 3: Imaging and the Liver
Chairs: Professor Neil Guha & Dr Ed Britton

15.25-15.35 MR Imaging for liver fibrosis
Dr Rohit Loomba

15.35-15.45 Metabolic imaging of the liver
Professor Penny Gowland

15.45-15.50 Q&A Session and Panel Discussion

15.50-15.55 BREAK
2020 - Programme

15.55-16.30 – Session 4: Williams Calne Lecture
Chairs: Dr Mark Aldersley & Dr Matt Armstrong

15.55-16.00  Obituaries
Professor Neil McIntyre
Professor Roger Williams

16.00-16.20  Williams Calne Lecture – Liver Frailty and pre-habilitation in the cirrhotic patient awaiting liver transplantation
Professor Jennifer Lai

16.20-16.30  Q&A Session

16.30-16.35  BREAK

16.35-17.30 – Session 5: Andy Burroughs Young Investigator Award
Chairs: Dr Andrew Yeoman & Professor Fiona Oakley

16.35-16.50  Andy Burroughs Young Investigator Award: The Scarred Liver Project
Dr Rebecca Harris

Free Papers
16.50-17.00  11 – L-Carnitine supplementation in Non-Alcoholic Fatty Liver Disease: Effects on intrahepatic triglyceride, muscle lipid fractions and liver mitochondrial energetics - results from a pilot randomised trial.
Dr Prarthana Thiagarajan

17.00-17.10  63 – Redefining poor prognostic criteria for acetaminophen-induced acute liver failure using regeneration and cell-death linked miRNA signatures
Dr Oliver Tavabie

17.10-17.20  72 – Late graft iron accumulation in patients transplanted for alcohol-related cirrhosis is associated with explant iron overload
Dr Meha Bhuva

17.20–17.25  Closing remarks

17.25-18.00  VIRTUAL EXHIBITION
Tuesday 22nd September 2020

11.00-11.30  Industry symposia sponsored by Shionogi
Changing times – opportunities for optimising management of severe thrombocytopenia with TPO-RAs
Professor Markus Peck-Radosavljevic
Dr Andy Holt
Helen Caldwell

11.00-11.30  Industry symposia sponsored by Norgine
Muscle matters in hepatic encephalopathy
Professor Debbie Shawcross
Dr Andrew Yeoman

11.30-11.55  VIRTUAL EXHIBITION

12.00-12.30  Industry symposia sponsored by Intercept
Risk stratification in PBC: could identifying senescence help?
Professor David Jones

12.00-12.30  Industry symposia sponsored by W L Gore
PORTAL HYPERTENSION & TIPPS: What does the future hold for 2020 and beyond?
Dr David Patch
Dr Dhiraj Tripathi
Professor Guru Aithal

12.30-12.55  VIRTUAL EXHIBITION

-----------------------------

TECHNOLOGY IN TRANSLATION SYMPOSIUM

13.00-13.40 – Session 6: Technology in Translation Symposium
Chairs: Professor Jude Oben & Professor Phil Newsome

13.00-13.15  Precision cut liver: modelling NAFLD and future targets for drug development
Professor Jelena Mann

13.15-13.30  Rare disease modelling: Hereditary NAFLD
Dr Jane Grove & Dr Nick Hannan

13.30-13.40  Q&A Session and Panel Discussion
13.42-14.17 – Session 7: British Liver Trust Lecture
   Chairs: Pamela Healy OBE & Professor Guru Aithal

13.42-13.47   Introduction to BLT Lecture
   Pamela Healy OBE

13.47-14.07   British Liver Trust Lecture – Blurring the boundaries of health care for
   chronic liver diseases
   Professor Neil Guha & Dr Jo Morling

14.07-14.17   Q&A Session and Panel Discussion

14.17-14.20   BREAK

14.20-15.20 – Session 8: Technology in Translation Symposium continued & Prize
   Lectures
   Chairs: Dr Jane Hartley & Professor Chris Goldring

14.20-14.35   Biomarkers and liver injury
   Professor James Dear

14.35-14.50   Dame Sheila Sherlock Research Award
   Dr Abhishek Chauhan

14.50-15.10   Alex Mowat Lecture - Advances in the management of inborn errors
   of metabolism.
   Professor Paul Gissen

15.10-15.20   Q&A Session and Panel Discussion

15.20-15.50   BREAK & VIRTUAL EXHIBITION

15.50-16.45 – Session 9: New Frontiers in Hepatology
   Chairs: Dr Vicky Snowden & Dr Deepak Joshi

15.50-16.05   Equality in Science
   Professor Mala Rao

16.05-16.20   Liver Regeneration and repair
   Professor Stuart Forbes

16.20-16.35   A Good death
   Dr Ben Hudson

16.35-16.45   Q&A Session and Panel Discussion

16.45-16.50   BREAK
16.50-17.20 – Session 10: Free Papers
Chairs: Professor Raj Mookerjee & Dr David Sheridan

16.50-17.00  35 – Changes in alcohol-related liver disease admissions over the time of minimum unit pricing of alcohol: the GRI Q4 study
Dr Sardar Chaudhary

17.00-17.10  54 – Methotrexate: an innocent bystander in the development of liver fibrosis, findings of the STrATIFY study
Dr Lucy Turner

17.10-17.20  58 – Amino acid substitution in genotype 3a hepatitis C virus polymerase protein affects responses to sofosbuvir and interferon alpha and inhibits apoptosis
Dr Wing-yiu Jason Lee

17.20-17.25  Closing remarks

17.25-18.00 VIRTUAL EXHIBITION
Wednesday 23rd September 2020

12.30-13.25  VIRTUAL EXHIBITION

12.45-13.10  BASL ANNUAL BUSINESS MEETING – Everyone Welcome

ASCITES SYMPOSIUM

13.30-14.25 – Session 11: Ascites Symposium
  Chairs: Professor Debbie Shawcross & Dr Rebecca Jones

  Professor Alastair O’Brien

13.45-14.00  Does albumin infusion prevent refractory ascites?
  Professor Paolo Caraceni

14.00-14.15  Long term drainage of refractory ascites in the patient with end stage liver disease – what is the case of need and what is the evidence?
  Professor Sumita Verma

14.15-14.25  Q&A Session and Panel Discussion

14.25-14.30  BREAK

14.30-15.20 – Session 12: The HCC-UK/BASL/NCRAS partnership & Ralph Wright Lecture
  Chairs: Dr Aileen Marshall & Dr Ian Rowe

14.30-14.50  HCC-UK/BASL/NCRAS partnership
  Dr Anya Burton

14.50-15.10  Ralph Wright Lecture - Accessible innovations to tackle global challenges: Cirrhosis and Hepatocellular carcinoma
  Professor Philip Johnson

15.10-15.20  Q&A Session and Panel Discussion

15.20-15.50  BREAK & VIRTUAL EXHIBTION

15.50-16.30 – Session 13: Free Papers
  Chairs: Dr Dhiraj Tripathi & Pinelopi Manousou

15.50-16.00  38 – Carvedilol versus endoscopic band ligation for secondary prophylaxis of variceal bleeding - long term follow-up of a multicentre randomised controlled study
  Dr Philip Dunne
16.00-16.10  86 – A genome-wide association study of severe alcoholic hepatitis
          Mr Moksh Sharma

16.10-16.20  95 – Exploring genetic variation of PDCD1, which encodes T-cell
          receptor PD-1, in patients with non-alcoholic fatty liver disease (NAFLD) and
          hepatocellular carcinoma (HCC)
          Professor Helen Reeves

16.20-16.30  99 – Hepatitis C Test and Treat Roadshow - Reaching homeless
          communities across the West Midlands, UK
          Mr Danny Morris

16.30-16.35  BREAK

16.35-18.00  – Session 14: The Impact of COVID-19 on liver patients and the
          Environment
          Chairs: Professor Michael Heneghan & Professor Matthew Cramp

16.35-16.50  COVID-HEP Registry
          Dr Tom Marjot

16.50-17.00  Free paper
          89 – Liver transplantation does not significantly increase risk of mortality from SARS-CoV-2 infection: International registry data
          Dr Gwilym Webb

17.00-17.15  Impact on transplantation services
          Professor Umberto Cillo

17.15-17.30  COVID19 and the environment
          Dr William Stableforth

17.30-17.45  Q&A Session and Panel Discussion

17.45-18.00  Final comments and close
          Professor Guru Aithal